# Pizarra — PT-pseudo_06b319f42fcb (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_06b319f42fcb
Task: 1

Encounter: Urology - outpatient on 24 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 13.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.452 ng/mL²
  - PSA velocity: 1.92 ng/mL/yr
  - Prior PSA: 12.3 ng/mL
  - Prostate volume: 29.86 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8947026 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypertension, COPD, Chronic kidney disease, Benign prostatic hyperplasia
  - Current medication: valsartan, metoprolol, tiotropium, salbutamol PRN, tamsulosin
  - Allergies: NSAIDs
  - Additional notes: PSA 13.5 ng/mL. PI-RADS 5. PSAD 0.45. Prostate volume 30 mL. csPCa 0.89.

Vitals: weight 84 kg, height 186 cm, BMI 24.3, BP 129/83 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Current clinical focus centers on reassessing known ISUP GG1 pathology alongside a PSA reading of 13.5 ng/mL.

History: A retired civil servant first entered investigation for elevated PSA markers in early 2023. The individual is married and shares a home with his partner. He maintains a strictly non-smoking status. Medical background includes hypertension, chronic obstructive pulmonary disease, chronic kidney disease, and benign prostatic hyperplasia. Current pharmacotherapy consists of valsartan, metoprolol, tiotropium, and salbutamol on a PRN basis, alongside tamsulosin for lower urinary tract symptoms. Cardiology and pulmonary assessments have recently confirmed stable parameters. Daily mobility includes a twenty-minute walking routine, though he experiences intermittent fatigue that does not correlate with physical activity. Lower urinary tract symptom severity registers at an IPSS score of 13. Two systematic biopsies performed in 2023 and 2024 both revealed Gleason 3+3 disease, placing him under ongoing surveillance. A routine colonoscopy and a recent influenza vaccination occurred without complication. He reports no alterations in bowel habits, unexplained weight shifts, hematuria, pelvic discomfort, or bone pain. Overall systemic health remains steady.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents with symmetrical enlargement and lacks any palpable nodules. Systemic assessment shows stable vital signs, recording a blood pressure of 129/83 mmHg and a regular heart rate of 64 bpm. Abdominal palpation yields no masses, and peripheral lymphatic examination remains entirely unremarkable.

Patient info: retired civil servant; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Gastroenterology — surveillance colonoscopy; GP practice nurse — flu vaccination.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.61 +/- 0.20   (95% CI 0.21-0.94)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.6 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=13.5, age=66.0, psad=0.452, dre_ord=0.0, vol=29.86, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=13.5, csPCa probability=0.8947) and failed to incorporate the crucial context of the prior positive biopsy (Gleason 3+3) and the specific trajectory of the PSA (12.3 to 13.5 ng/mL). It did not weigh the clinical significance of the prior diagnosis against the current high-risk imaging findings.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability, but the guideline criterion explicitly states the decision is undetermined by the panel because the prior positive biopsy means the question shifts from "does he have cancer" to "is the lesion stable/progressed," which the panel cannot resolve. The prior's suggestion of 'BIOPSY' is potentially wrong because it ignores the protocol's finding that the decision hinges entirely on retrieved documents.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context on prior biopsy findings
laboratory panel - full panel
family-history anamnesis

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Prostate mpMRI | Date: 10 February 2025 | Department: Radiology
PI-RADS 5 lesion in the right mid-gland peripheral zone.
The lesion is 14 x 12 x 10 mm, shows diffusion restriction, and early focal enhancement. No extraprostatic extension or seminal vesicle invasion is identified.

get_psa_trend
PSA trend shows a rising trajectory: 4.2 ng/mL (Mar 2023) -> 6.2 ng/mL (Nov 2023) -> 9.1 ng/mL (Jun 2024) -> 13.5 ng/mL (Feb 2025).

get_previous_notes
27 Oct 2024: Biopsy in 2023 established ISUP GG1 disease. Subsequent testing in June 2024 yielded a PSA reading of 12.3 ng/mL.
29 Jun 2024: Pathology from that session returned Gleason 3+3, ISUP GG 1.

get_lab_results
PSA: 13.5 ng/mL (19 Jan 2025, H).
%Free PSA: 19% (19 Jan 2025).
eGFR: <60 mL/min/1.73m2 (19 Jan 2025, L).

NOT RETRIEVED
The family-history anamnesis was not retrieved, which could potentially provide context regarding the patient's risk profile.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling:
- PI-RADS 5 lesion in the right mid-gland peripheral zone.
- PSA velocity is high (1.92 ng/mL/yr, based on the initial record, though the trend shows a rise).
- The prior biopsy showed Gleason 3+3 disease, and the current PSA is significantly elevated (13.5 ng/mL).

AGAINST Sampling:
- Prior biopsy showed ISUP GG1 disease.
- The MRI report does not explicitly state if the current lesion is new or larger compared to the previous study.

WHERE THIS LEANS
The evidence strongly suggests that the high-risk imaging (PI-RADS 5) combined with a significant PSA rise, despite a prior low-grade diagnosis, warrants further investigation to characterize the current lesion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior diagnosis of ISUP GG1 disease, the combination of a PI-RADS 5 lesion and a significant PSA rise from 12.3 ng/mL to 13.5 ng/mL warrants further characterization. The evidence retrieved shows the PI-RADS 5 lesion and the PSA trend, which together push the decision toward sampling. The prior biopsy result of Gleason 3+3 is documented, but the lack of a comparison against a previous MRI means the current lesion status is unknown, making biopsy informative.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
